ABAlain Bitton

Alain Bitton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alain Bitton has a total of 237 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study

    by Panu Wetwittayakhlang, Christine Verdon, Michael Starr, Gustavo Drügg Hahn, Petra A. Golovics, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Peter L. Lakatos

    Background: Endoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn’s disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn’s disease. Methods: This prospective, open-label, single-arm study included Crohn’s disease patients with moderate–severe endoscopic proximal small bowel involvement, defined by a Lewis score >790. Patients were treated with adalimumab monotherapy for 24 weeks. Co-primary outcomes were endoscopic healing, defined as Lewis score 50% decrease in Lewis score. Secondary outcomes included clinical (Harvey–Bradshaw index <4) and biomarker remission (fecal calprotectin <250 μg/g, and C-reactive protein <5 mg/L). Results: A total of 59 Crohn’s disease patients were screened; 17 patients have met eligibility criteria and were enrolled. Endoscopic healing was observed in 8 patients (47.1%) and endoscopic response in additional 5 patients (29.4%) at 24 weeks. Median Lewis score was significantly decreased compared to baseline (1912 vs. 337, P = .0005). Eleven of 13 patients (84.6%) with clinical activity achieved clinical remission (baseline: 13/17 vs. week 24: 2/17, P < .0001). Nine of 10 patients with elevated C-reactive protein achieved normal C-reactive protein after treatment and the median C-reactive protein significantly decreased from 7.4 to 1.6 mg/L, P = .032. In contrast, no change was observed in fecal calprotectin pre- and posttreatment. Conclusions: Adalimumab induced endoscopic healing and clinical remission in patients with active small bowel Crohn’s disease, with approximately half of the patients achieving endoscopic healing.


  • Open Access

    The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary

    by Joseph W Windsor, M Ellen Kuenzig, Sanjay K Murthy, Alain Bitton, Charles N Bernstein, Jennifer L Jones, Kate Lee, Laura E Targownik, Juan-Nicolás Peña-Sánchez, Noelle Rohatinsky, et al.

    The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn’s and Colitis Canada’s 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.


  • THE MEDICAL CARE PROCESS OF INFLAMMATORY BOWEL DISEASES IN CANADA: PERCEPTIONS OF PATIENTS AND PROVIDERS

    by Sophie Veilleux, Jolyane Blouin Bougie, Isabelle Noiseux, Alain Bitton, Luc Vachon, Brian White Guay, John D. Rioux

  • Open Access

    Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study

    by Panu Wetwittayakhlang, Petra A Golovics, Alex Al Khoury, Elie Ganni, Gustavo Drügg Hahn, Albert Cohen, Jonathan Wyse, Marc Bradette, Talat Bessissow, Waqqas Afif, et al.

    Background and Aims: Objective monitoring and effective early treatment using a treat-to-target approach are key to improving therapeutic outcomes in IBD patients. This study aimed to assess adherence to objective monitoring (clinical, biomarkers, and endoscopy) and its impact on clinical outcomes. Methods: A prospective, multicenter study included consecutive IBD patients starting on adalimumab therapy between January 2019 and December 2020. Disease activity, assessed by the Harvey-Bradshaw index (HBI), partial Mayo, C-reactive protein (CRP), fecal calprotectin (FCAL), and endoscopy were evaluated at adalimumab initiation and 3, 6, 9 and 12 months. Therapeutic drug monitoring, changes in treatment, drug sustainability, and clinical outcomes were assessed. Results: 104 IBD patients were enrolled (78.8% CD, median age 34.3 years, disease duration 9 years). During the 12 months follow-up, high adherence to clinical activity assessment was observed in both CD (81.3%- 87.7%) and UC patients (76.5-90.9%). CRP measurement decreased over time in both CD (37.3%-54.9%) and UC (29.4%-50.0%). The adherence to serial FCAL monitoring was low in CD (22.7-31.3%) and UC patients (17.6-56.0%). UC patients had higher adherence to early endoscopic assessment (<6 months) compared to CD patients (40.9% vs. 21.5%). Adherence to early combined clinical and biomarkers resulted in earlier dose optimization in CD and UC (log-rank<0.001), but drug sustainability was not different. The patients with early combined adherence had a significantly higher clinical remission rate at 1 year compared to non-adherence (70.2% vs. 29.8%, p=0.007) but no significant difference in UC patients. Conclusions: The adherence to early objective monitoring with combined clinical and biomarkers assessment in IBD patients starting adalimumab therapy led to dose optimization and improved 1-year clinical remission in CD but did not change drug sustainability and clinical remission in UC.


  • Open Access

    Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

    by Gustavo Drügg Hahn, Petra Anna Golovics, Panu Wetwittayakhlang, Dirlene Melo Santa Maria, Usiara Britto, Gary Edward Wild, Waqqas Afif, Alain Bitton, Talat Bessissow, Peter Laszlo Lakatos

    Background and Aim: Newer biologics appeared safer in landmark clinical trials, but their safety is understudied in vulnerable populations. The aim of the present study was to perform a systematic review and meta-analysis to assess the safety of available biologicals in the elderly IBD population. Methods: We systematically searched PubMed/Medline and conference proceedings between 1 April 1969 and 1 June 2021 to identify eligible studies that examined the safety of biologics in elderly patients with IBD. Of the 2885 articles and 12 congress abstracts identified, 12 peer reviewed papers and 3 abstracts were included after independent evaluation by two reviewers. The identified studies collected safety data on anti-TNF, vedolizumab (VDZ) and ustekinumab (UST). Results: Rates of AE and infections were not different among the biologics (AE mean rate: 11.3 (CI 95% 9.9–12.7)/100 pts-years; p = 0.11, infection mean rate: 9.5 (CI 95% 8.4–10.6)/100 pts-years; p = 0.56) in elderly IBD patients on anti-TNF, VDZ or UST. Infusion/injection reaction rates were more common on anti-TNFs (mean rate: 2.51 (CI 95% 1.7–3.4/100 pts-years; p = 0.02). and malignancy rates were higher on VDZ/UST (mean rate: 2.14 (CI 95% 1.6–2.8)/100 pts-years; p = 0.01). Conclusions: Rates of AEs and infections were not different among biologicals. Infusion/injection reactions were more common on anti-TNFs. Current data are insufficient to suggest the sequencing of biologicals in elderly patients based on safety.


  • Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.

    by Pauline Rivière, Caitlyn Kanters, Alexander Ni, Gauthier Pellet, Marianne Hupé, Nesrine Aboulhamid, Florian Poullenot, Alain Bitton, Frank Zerbib, Peter L. Lakatos, et al.

  • Tu1441: EVALUATING DRUG SUSTAINABILITY, EFFICACY AND SAFETY OF BIOLOGIC AGENTS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER RETROSPECTIVE STUDY

    by Petra A. Golovics, Jean-Frederic Leblanc, Gustavo Hahn, Panu Wetwittayakhlang, Abdulrahman Qatomah, Anna Wang, Levon Boodaghians, Jeremy Liu Chen Kiow, Maryam Al Ali, Gary Wild, et al.

  • Mo1566: MUCOSAL HEALING AND CLINICAL REMISSION AFTER TREATMENT WITH ADALIMUMAB IN SMALL INTESTINAL CROHN’S DISEASE (SIMCHA STUDY): FINAL RESULTS FROM A PROSPECTIVE, OPEN-LABEL, SINGLEARM STUDY

    by Panu Wetwittayakhlang, Petra A. Golovics, Gustavo Hahn, Talat Bessissow, Alain Bitton, Waqqas Afif, Gary Wild, Peter L. Lakatos

  • Open Access

    Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015

    by Petra Anna Golovics, Christine Verdon, Panu Wetwittayakhlang, Christopher Filliter, Lorant Gonczi, Gustavo Drügg Hahn, Gary E. Wild, Waqqas Afif, Alain Bitton, Talat Bessissow, et al.

    Background: Chronic inflammatory diseases are linked to an increased risk of atherothrombotic events, but the risk associated with inflammatory bowel disease (IBD) is controversial. We therefore examined the risk of and risk factors for myocardial infarction (MI) and stroke in IBD patients. Methods: We used the public health administrative database from the Province of Quebec, Canada, to identify IBD patients newly diagnosed between 1996 and 2015. The incidence and prevalence of MI and stroke in IBD patients were compared to those for the Canadian population. Results: A cohort of 35,985 IBD patients was identified. The prevalence but not incidence rates of MI were higher in IBD patients (prevalence: 3.98%; incidence: 0.234) compared to the Canadian rates (prevalence: 2.0%; incidence: 0.220), while the prevalence and incidence rates of stroke were not significantly higher in the IBD patients (prevalence: 2.98%; incidence: 0.122, vs. Canadian rates: prevalence: 2.60%; incidence: 0.297). We identified age, female gender, hyperlipidemia, diabetes, and hypertension (p < 0.001 for each) as significant risk factors associated with MI and stroke in IBD. Exposure to biologics was associated with a higher incidence of MI (IRR: 1.51; 95% CI: 0.82–2.76; p = 0.07) in the insured IBD population. Conclusions: An increased prevalence but not incidence of MI and no increased risk of stroke were identified in this population-based IBD cohort.


  • Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort

    by A. Al Khoury, Y. Xiao, P.A. Golovics, R. Kohen, W. Afif, G. Wild, G. Friedman, P. Galiatsatos, N. Hilzenrat, A. Szilagyi, et al.